Catalyst has developed and optimized a proprietary method to create novel proteases that includes anti-C3 protease assets such as CB 2782 for dry age-related macular degeneration (dAMD) and ischemia-reperfusion injury such as delayed graft function (DGF) after kidney transplantation.

In October 2017, Catalyst announced a strategic collaboration with Mosaic Biosciences to develop intravitreal anti-complement factor 3 (C3) products for the treatment of dry AMD and other serious inflammatory retinal diseases. Mosaic will improve the pharmacokinetic (PK) properties of Catalyst’s lead anti-C3 proteases, with the goal of delivering product candidates that have a target profile of at least once quarterly intravitreal (IVT) dosing in humans and better potency compared with competitors with monthly or bi-monthly dosing. Catalyst maintains global commercial rights and these assets are available for partnering. Please contact our Business Development team for further information.

The complement cascade is a series of molecular processes that plays a central role in the body’s inflammatory and immune responses and helps to localize specific immune system cells at the site of infection or inflammation. In particular, C3 is a clinically validated target for the treatment of Geographic Atrophy (GA), a late-stage form of dAMD.

CB 2782 is a novel protease derived from human membrane type serine protease 1 (MTSP-1) that selectively cleaves C3 and has been shown to completely inhibit C3 in non-human primate studies with good tolerability after intraocular administration.